B+
Bull case
25%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
ECOR
electroCoreFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$6.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+27.0
Score
AI commentary
Primary-source support is solid, but the thesis remains cautious. ECOR exited 2025 with genuine revenue momentum and a 2026 growth guide, yet the balance sheet, concentration risk, and leadership change keep this in low-conviction monitoring territory rather than a strong bullish setup.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-01eventPost-CEO transition execution resetHigh impact
Management transition is now live after the March 19, 2026 announcement that CEO Dan Goldberger would retire effective April 1, 2026, with CFO Joshua Lev becoming interim President and Michael Fox joining as COO; the stock likely needs evidence that channel momentum survives the handoff [#8-K-2026-03-19].
2026-05-15catalystNear-term funding and listing watch around the next filing windowHigh impact
The key near-term risk check is whether Q1 2026 results show enough cash discipline to avoid a dilutive financing overhang: the 10-K said forecast cash is insufficient for the next 12 months, raised substantial doubt about going concern, showed total cash of $11.6 million, stockholders' deficit of $(1.7) million, and flagged potential Nasdaq compliance pressure if market value or equity tests are missed [#10-K-2026-03-19].
2026-12-31catalyst2026 growth guide must convert into VA/Rx and wellness sell-throughHigh impact
The main upside path is simple but still unproven: 2025 net sales rose 27% to $32.0 million, U.S. prescription sales grew 25%, general wellness sales grew 97%, and management guided to approximately 30% revenue growth for 2026; sustained execution against that guide would matter more than narrative alone [#8-K-2026-03-19] [#10-K-2026-03-19].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology